Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 27, 1997New England Journal of Medicine

Management of Multiple Sclerosis

View Full Paper
Ask AI
Bookmark
Share

Authors

RRRichard A. RudickNorwalk HospitalJCJeffrey A. CohenDartmouth HealthBWBianca Weinstock‐GuttmanECD for the Masses (United States)

Discussion

Loading...

Member takes

Implication

Challenges view of MS as untreatable; leaves open need for confirmatory trials before practice change.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rudick et al. (1997) studied this question.

synapsesocial.com/papers/6a1bc1b801af05bf0da8e987https://doi.org/10.1056/nejm199711273372207
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.1995 · 113 citations
  2. 2Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production.1994 · 214 citations
  3. 3Relapsing transverse myelitis1991 · 61 citations
  4. 4Risk of cancer from azathioprine therapy in multiple sclerosis1996 · 203 citations
  5. 5Interferon beta‐lb in the treatment of multiple sclerosis1995 · 918 citations